Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases.
暂无分享，去创建一个
A. Howell | L. Dirix | A. V. van Oosterom | D. Dodwell | J. Body | R. Rubens | R. Coleman | R. Becher | G. White | M. Tubiana‐Hulin
[1] S. Ralston,et al. COMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIA , 1989, The Lancet.
[2] J. Hermans,et al. REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT , 1987, The Lancet.
[3] O. Bijvoet,et al. INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.) , 1979, The Lancet.